Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Letter

Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury

Barry Dixon1*, Marcus J Schultz2, Jorrit J Hofstra2, Duncan J Campbell34 and John D Santamaria1

Author Affiliations

1 Department of Intensive Care St. Vincent's Hospital, 41 Victoria Parade, Fitzroy, Melbourne, Victoria, 3065, Australia

2 Department of Intensive Care Medicine & Laboratory of Experimental Intensive Care and Anesthesiology, The Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

3 St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Melbourne, Victoria, 3065

4 Department of Medicine, The University of Melbourne, Clinical Sciences Building, 29 Regent Street, Fitzroy, Melbourne, Victoria, 3065, Australia

For all author emails, please log on.

Critical Care 2010, 14:445  doi:10.1186/cc9269


See related research by Dixon et al., http://ccforum.com/content/12/3/R64

Published: 20 October 2010

First paragraph (this article has no abstract)

Previously in this journal, we published a phase 1 study of nebulized heparin in patients with acute lung injury [1]. Patients were administered heparin at doses of 50,000, 100,000, 200,000, or 400,000 U/day for 2 days, and bronchoalveolar lavage (BAL) fluid samples were taken at baseline and after the last heparin dose. The study demonstrated a trend to reduced coagulation activation (prothrombin fragments) in BAL fluid after the last dose of nebulized heparin [1].